Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the ri...
Approximately 600 patients expected to be enrolled at clinical sites across the United States, Europe, China and South America Global Phase 3 program, R...
HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...
Novartis announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of red...
Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the Phase Ib/IIa clinical results of its anti-S...
Resonant Clinical Solutions, a global clinical solutions partner serving life sciences organizations across the clinical supply chain and sample lifecycl...
ONWARD Medical N.V., the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, announces ...
BioMed X, a leading innovation engine for pharma, announced the relocation of its global headquarters to LAB22 at Heidelberg Innovation Park (hip), toget...
- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of p...
Evonik is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The facility will increase Evoni...
Roche announced new two-year data from the Phase IIIb/IV SALWEEN study of Vabysmo® (faricimab), presented at the 19th Asia-Pacific Vitreo-retina Soci...
At INTERPHEX, sustainability and supply chain performance emerged as important priorities for pharmaceutical packaging. John Jansen, Head of Global Marketi...
Lakefront Biotherapeutics NV announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the ...
Announcing expansion of capabilities to provide customers with a broader range of DNA synthesis solutions, allowing IDT to complement and extend ...
© 2026 Biopharma Boardroom. All Rights Reserved.
